Bone marrow dendritic cells are reduced in patients with high-risk myelodysplastic syndromes

Leukemia Research

Volumn 37, Issue 3, 2013, Pages 266-273

  Saft, Leonie ^a   Björklund, Elisabet ^a   Berg, Elisabeth ^b   Hellström Lindberg, Eva ^a   Porwit, Anna ^a,c  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b KAROLINSKA INSTITUTE   (Sweden)

^c TORONTO GENERAL HOSPITAL   (Canada)

Author keywords

Bone marrow; Dendritic cells; Flow cytometry; International Prognostic Scoring System (IPSS); Myelodysplastic syndromes

Indexed keywords

ADOLESCENT; ADULT; AGED; ARTICLE; BONE MARROW CELL; CELL DIFFERENTIATION; CELL LINEAGE; CELL STRUCTURE; CHILD; COHORT ANALYSIS; CONTROLLED STUDY; CYTOGENETICS; DENDRITIC CELL; FEMALE; FLOW CYTOMETRY; HIGH RISK PATIENT; HUMAN; HUMAN TISSUE; IMMUNOSURVEILLANCE; INFANT; INTERNATIONAL PROGNOSTIC SCORING SYSTEM; MAJOR CLINICAL STUDY; MALE; MORPHOLOGY; MYELODYSPLASTIC SYNDROME; MYELOID PROGENITOR CELL; NEUTROPHIL COUNT; OVERALL SURVIVAL; PRESCHOOL CHILD; PRIORITY JOURNAL; SCHOOL CHILD; THROMBOCYTE COUNT;

ADOLESCENT; ADULT; AGED; BONE MARROW CELLS; CASE-CONTROL STUDIES; CELL COUNT; CHILD; CHILD, PRESCHOOL; DENDRITIC CELLS; DOWN-REGULATION; FEMALE; HUMANS; INFANT; INFANT, NEWBORN; MALE; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; RISK; SEVERITY OF ILLNESS INDEX; YOUNG ADULT;

EID: 84872918381     PISSN: 01452126     EISSN: 18735835     Source Type: Journal    
DOI: 10.1016/j.leukres.2012.10.010     Document Type: Article

References (66)

1. Jones P.A., Baylin S.B. The fundamental role of epigenetic events in cancer. Nat Rev Genet 2002, 3(6):415-428.
2. Catenacci D.V., Schiller G.J. Myelodysplasic syndromes: a comprehensive review. Blood Rev 2005, 19(6):301-319.
3. Nolte F., Hofmann W.K. Molecular mechanisms involved in the progression of myelodysplastic syndrome. Future Oncol 2010, 6(3):445-455.
4. Nimer S.D. MDS: a stem cell disorder-but what exactly is wrong with the primitive hematopoietic cells in this disease?. Hematol Am Soc Hematol Educ Program 2008, 2008(1):43-51.
5. Bejar R., Levine R., Ebert B.L. Unraveling the molecular pathophysiology of myelodysplastic syndromes. J Clin Oncol 2011, 29(5):504-515.
6. Alfinito F., Sica M., Luciano L., Pepa R.D., Palladino C., Ferrara I., et al. Immune dysregulation and dyserythropoiesis in the myelodysplastic syndromes. Br J Haematol 2010, 148(1):90-98.
7. Kook H., Zeng W., Guibin C., Kirby M., Young N.S., Maciejewski J.P. Increased cytotoxic T cells with effector phenotype in aplastic anemia and myelodysplasia. Exp Hematol 2001, 29(11):1270-1277.
8. Jonasova A., Neuwirtova R., Cermak J., Vozobulova V., Mocikova K., Siskova M., et al. Cyclosporin A therapy in hypoplastic MDS patients and certain refractory anaemias without hypoplastic bone marrow. Br J Haematol 1998, 100(2):304-309.
9. Molldrem J.J., Caples M., Mavroudis D., Plante M., Young N.S., Barrett A.J. Antithymocyte globulin for patients with myelodysplastic syndrome. Br J Haematol 1997, 99(3):699-705.
10. Molldrem J.J., Jiang Y.Z., Stetler-Stevenson M., Mavroudis D., Hensel N., Barrett A.J. Haematological response of patients with myelodysplastic syndrome to antithymocyte globulin is associated with a loss of lymphocyte-mediated inhibition of CFU-GM and alterations in T-cell receptor Vbeta profiles. Br J Haematol 1998, 102(5):1314-1322.
11. Kochenderfer J.N., Kobayashi S., Wieder E.D., Su C., Molldrem J.J. Loss of T-lymphocyte clonal dominance in patients with myelodysplastic syndrome responsive to immunosuppression. Blood 2002, 100(10):3639-3645.
12. Killick S.B., Mufti G., Cavenagh J.D., Mijovic A., Peacock J.L., Gordon-Smith E.C., et al. A pilot study of antithymocyte globulin (ATG) in the treatment of patients with 'low-risk' myelodysplasia. Br J Haematol 2003, 120(4):679-684.
13. Broliden P.A., Dahl I.M., Hast R., Johansson B., Juvonen E., Kjeldsen L., et al. Antithymocyte globulin and cyclosporine A as combination therapy for low-risk non-sideroblastic myelodysplastic syndromes. Haematologica 2006, 91(5):667-670.
14. Sloand E.M., Rezvani K. The role of the immune system in myelodysplasia: implications for therapy. Semin Hematol 2008, 45(1):39-48.
15. Baumann S., Krueger A., Kirchhoff S., Krammer P.H. Regulation of T cell apoptosis during the immune response. Curr Mol Med 2002, 2(3):257-272.
16. Sloand E.M., Mainwaring L., Fuhrer M., Ramkissoon S., Risitano A.M., Keyvanafar K., et al. Preferential suppression of trisomy 8 compared with normal hematopoietic cell growth by autologous lymphocytes in patients with trisomy 8 myelodysplastic syndrome. Blood 2005, 106(3):841-851.
17. Epperson D.E., Nakamura R., Saunthararajah Y., Melenhorst J., Barrett A.J. Oligoclonal T cell expansion in myelodysplastic syndrome: evidence for an autoimmune process. Leuk Res 2001, 25(12):1075-1083.
18. Pellagatti A., Cazzola M., Giagounidis A.A., Malcovati L., Porta M.G., Killick S., et al. Gene expression profiles of CD34+ cells in myelodysplastic syndromes: involvement of interferon-stimulated genes and correlation to FAB subtype and karyotype. Blood 2006, 108(1):337-345.
19. Zeng W., Miyazato A., Chen G., Kajigaya S., Young N.S., Maciejewski J.P. Interferon-gamma-induced gene expression in CD34 cells: identification of pathologic cytokine-specific signature profiles. Blood 2006, 107(1):167-175.
20. Micheva I., Thanopoulou E., Michalopoulou S., Kakagianni T., Kouraklis-Symeonidis A., Symeonidis A., et al. Impaired generation of bone marrow CD34-derived dendritic cells with low peripheral blood subsets in patients with myelodysplastic syndrome. Br J Haematol 2004, 126(6):806-814.
21. Ma L., Delforge M., van D., Verhoef V., Emanuel G., Boogaerts B.M., et al. Circulating myeloid and lymphoid precursor dendritic cells are clonally involved in myelodysplastic syndromes. Leukemia 2004, 18(9):1451-1456.
22. Ma L., Ceuppens J., Kasran A., Delforge M., Boogaerts M., Vandenberghe P. Immature and mature monocyte-derived dendritic cells in myelodysplastic syndromes of subtypes refractory anemia or refractory anemia with ringed sideroblasts display an altered cytokine profile. Leuk Res 2007, 31(10):1373-1382.
23. Swerdlow S.H., Campo E., Harris NLea. WHO classification of tumours of haematopoietic and lymphoid tissues 2008, IARC, Lyon. 8th ed.
24. Greenberg P., Cox C., LeBeau M.M., Fenaux P., Morel P., Sanz G., et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 1997, 89(6):2079-2088.
25. Malcovati L., Germing U., Kuendgen A., Della Porta M.G., Pascutto C., Invernizzi R., et al. Time-dependent prognostic scoring system for predicting survival and leukemic evolution in myelodysplastic syndromes. J Clin Oncol 2007, 25(23):3503-3510.
26. Kerndrup G., Pallesen G., Melsen F., Mosekilde L. Histomorphometrical determination of bone marrow cellularity in iliac crest biopsies. Scand J Haematol 1980, 24(2):110-114.
27. Hartsock R.J., Smith E.B., Petty C.S. Normal variations with aging of the amount of hematopoietic tissue in bone marrow from the anterior iliac crest. A study made from 177 cases of sudden death examined by necropsy. Am J Clin Pathol 1965, 43:326-331.
28. Thiele J., Kvasnicka H.M., Facchetti F., Franco V., van der Walt J., Orazi A. European consensus on grading bone marrow fibrosis and assessment of cellularity. Haematologica 2005, 90(8):1128-1132.
29. Bjorklund E., Mazur J., Soderhall S., Porwit-MacDonald A. Flow cytometric follow-up of minimal residual disease in bone marrow gives prognostic information in children with acute lymphoblastic leukemia. Leukemia 2003, 17(1):138-148.
30. Szabolcs P., Park K.D., Reese M., Marti L., Broadwater G., Kurtzberg J. Absolute values of dendritic cell subsets in bone marrow, cord blood, and peripheral blood enumerated by a novel method. Stem Cells 2003, 21(3):296-303.
31. Kotsianidis I., Bouchliou I., Nakou E., Spanoudakis E., Margaritis D., Christophoridou A.V., et al. Kinetics, function and bone marrow trafficking of CD4+CD25+FOXP3+ regulatory T cells in myelodysplastic syndromes (MDS). Leukemia 2009, 23(3):510-518.
32. Kordasti S.Y., Ingram W., Hayden J., Darling D., Barber L., Afzali B., et al. CD4+CD25high Foxp3+ regulatory T cells in myelodysplastic syndrome (MDS). Blood 2007, 110(3):847-850.
33. Mohty M., Jarrossay D., Lafage-Pochitaloff M., Zandotti C., Briere F., de Lamballeri X.-N., et al. Circulating blood dendritic cells from myeloid leukemia patients display quantitative and cytogenetic abnormalities as well as functional impairment. Blood 2001, 98(13):3750-3756.
34. Rigolin G.M., Della P.M., Bigoni R., Tieghi A., Cuneo A., Castoldi G. Dendritic cells in acute promyelocytic leukaemia. Br J Haematol 2001, 114(4):830-833.
35. Kufner S., Zitzelsberger H., Kroell T., Pelka-Fleischer R., Salem A., de Vallez F., et al. Leukaemia-derived dendritic cells can be generated from blood or bone marrow cells from patients with myelodysplasia: a methodological approach under serum-free culture conditions. Scand J Immunol 2005, 62(1):75-85.
36. Woiciechowsky A., Regn S., Kolb H.J., Roskrow M. Leukemic dendritic cells generated in the presence of FLT3 ligand have the capacity to stimulate an autologous leukemia-specific cytotoxic T cell response from patients with acute myeloid leukemia. Leukemia 2001, 15(2):246-255.
37. Dreyssig J., Kremser A., Liepert A., Grabrucker C., Freudenreich M., Schmid C., et al. Various 'dendritic cell antigens' are already expressed on uncultured blasts in acute myeloid leukemia and myelodysplastic syndromes. Immunotherapy 2011, 3(9):1113-1124.
38. Wang H.Q., Shao Z.H., Xing L.M., Fu R., Tu M.F., Sun J., et al. The quantity, subsets and expression of costimulatory molecules of circulating dendritic cells in the patients with myelodysplastic syndromes. Zhonghua Xue Ye Xue Za Zhi 2007, 28(7):474-477.
39. Matarraz S., Lopez A., Barrena S., Fernandez C., Jensen E., Flores J., et al. The immunophenotype of different immature, myeloid and B-cell lineage-committed CD34+ hematopoietic cells allows discrimination between normal/reactive and myelodysplastic syndrome precursors. Leukemia 2008, 22(6):1175-1183.
40. Reis-Alves S.C., Traina F., Saad S.T., Metze K., Lorand-Metze I. The impact of several phenotypic features at diagnosis on survival of patients with myelodysplastic syndromes. Neoplasma 2010, 57(6):530-536.
41. Almand B., Resser J.R., Lindman B., Nadaf S., Clark J.I., Kwon E.D., et al. Clinical significance of defective dendritic cell differentiation in cancer. Clin Cancer Res 2000, 6(5):1755-1766.
42. Hoffmann T.K., Muller-Berghaus J., Ferris R.L., Johnson J.T., Storkus W.J., Whiteside T.L. Alterations in the frequency of dendritic cell subsets in the peripheral circulation of patients with squamous cell carcinomas of the head and neck. Clin Cancer Res 2002, 8(6):1787-1793.
43. Della B.S., Gennaro M., Vaccari M., Ferraris C., Nicola S., Riva A., et al. Altered maturation of peripheral blood dendritic cells in patients with breast cancer. Br J Cancer 2003, 89(8):1463-1472.
44. Laane E., Bjorklund E., Mazur J., Lonnerholm G., Soderhall S., Porwit A. Dendritic cell regeneration in the bone marrow of children treated for acute lymphoblastic leukaemia. Scand J Immunol 2007, 66(5):572-583.
45. Mami N.B., Mohty M., Chambost H., Gaugler B., Olive D. Blood dendritic cells in patients with acute lymphoblastic leukaemia. Br J Haematol 2004, 126(1):77-80.
46. Maecker B., Mougiakakos D., Zimmermann M., Behrens M., Hollander S., Schrauder A., et al. Dendritic cell deficiencies in pediatric acute lymphoblastic leukemia patients. Leukemia 2006, 20(4):645-649.
47. Liu Y.J. Dendritic cell subsets and lineages, and their functions in innate and adaptive immunity. Cell 2001, 106(3):259-262.
48. Steinman R.M. The dendritic cell advantage: new focus for immune-based therapies. Drug News Perspect 2000, 13(10):581-586.
49. Wu L., D'Amico A., Hochrein H., O'Keeffe M., Shortman K., Lucas K. Development of thymic and splenic dendritic cell populations from different hemopoietic precursors. Blood 2001, 98(12):3376-3382.
50. Galy A., Travis M., Cen D., Chen B. Human T, B, natural killer, and dendritic cells arise from a common bone marrow progenitor cell subset. Immunity 1995, 3(4):459-473.
51. Caux C., Vanbervliet B., Massacrier C., Dubois B., de Saint Vis B., Fayette J., et al. In vitro regulation of development and function of dendritic cells. Hematol Cell Ther 1996, 38(5):463.
52. Manz M.G., Traver D., Miyamoto T., Weissman I.L., Akashi K. Dendritic cell potentials of early lymphoid and myeloid progenitors. Blood 2001, 97(11):3333-3341.
53. Ardavin C., Martinez del H.G., Martin P., Anjuere F., Arias C.F., Marin A.R., et al. Origin and differentiation of dendritic cells. Trends Immunol 2001, 22(12):691-700.
54. Banchereau J., Steinman R.M. Dendritic cells and the control of immunity. Nature 1998, 392(6673):245-252.
55. Traver D., Akashi K., Manz M., Merad M., Miyamoto T., Engleman E.G., et al. Development of CD8alpha-positive dendritic cells from a common myeloid progenitor. Science 2000, 290(5499):2152-2154.
56. Martin P., del Hoyo G.M., Anjuere F., Ruiz S.R., Arias C.F., Marin A.R., et al. Concept of lymphoid versus myeloid dendritic cell lineages revisited: both CD8alpha(-) and CD8alpha(+) dendritic cells are generated from CD4(low) lymphoid-committed precursors. Blood 2000, 96(7):2511-2519.
57. Lorand-Metze I., Ribeiro E., Lima C.S., Batista L.S., Metze K. Detection of hematopoietic maturation abnormalities by flow cytometry in myelodysplastic syndromes and its utility for the differential diagnosis with non-clonal disorders. Leuk Res 2007, 31(2):147-155.
58. Ribeiro E., Matarraz Sudón S., de Santiago M., Lima C.S., Metze K., Giralt M., et al. Maturation-associated immunophenotypic abnormalities in bone marrow B-lymphocytes in myelodysplastic syndromes. Leuk Res 2006, 30(1):9-16.
59. Aggarwal S., van de Loosdrecht A.A., Alhan C., Ossenkoppele G.J., Westers T.M., Bontkes H.J. Role of immune responses in the pathogenesis of low-risk MDS and high-risk MDS: implications for immunotherapy. Br J Haematol 2011, 153(5):568-581.
60. Passweg J.R., Giagounidis A.A., Simcock M., Aul C., Dobbelstein C., Stadler M., et al. Immunosuppressive therapy for patients with myelodysplastic syndrome: a prospective randomized multicenter phase III trial comparing antithymocyte globulin plus cyclosporine with best supportive care-SAKK 33/99. J Clin Oncol 2011, 29(3):303-309.
61. Olnes M.J., Sloand E.M. Targeting immune dysregulation in myelodysplastic syndromes. JAMA 2011, 305(8):814-819.
62. Kiladjian J.J., Visentin G., Viey E., Chevret S., Eclache V., Stirnemann J., et al. Activation of cytotoxic T-cell receptor gammadelta T lymphocytes in response to specific stimulation in myelodysplastic syndromes. Haematologica 2008, 93(3):381-389.
63. Van T., Van d V., Van V., Cools D.A., Anguille N., Ladell S.K., et al. Induction of complete and molecular remissions in acute myeloid leukemia by Wilms' tumor 1 antigen-targeted dendritic cell vaccination. Proc Natl Acad Sci USA 2010, 107(31):13824-13829.
64. Lee A.W., Truong T., Bickham K., Fonteneau J.F., Larsson M., Da Silva I., et al. A clinical grade cocktail of cytokines and PGE2 results in uniform maturation of human monocyte-derived dendritic cells: implications for immunotherapy. Vaccine 2002, 20(Suppl. 4):A8-A22.
65. Westers T.M., Stam A.G., Scheper R.J., Regelink J.C., Nieuwint A.W., Schuurhuis G.J., et al. Rapid generation of antigen-presenting cells from leukaemic blasts in acute myeloid leukaemia. Cancer Immunol Immunother 2003, 52(1):17-27.
66. Kremser A., Dressig J., Grabrucker C., Liepert A., Kroell T., Scholl N., et al. Dendritic cells (DCs) can be successfully generated from leukemic blasts in individual patients with AML or MDS: an evaluation of different methods. J Immunother 2010, 33(2):185-199.